MedPath

Multi-institutional survey of thoracic endovascular aortic repair for patients with esophageal cancer

Not Applicable
Conditions
Esophageal cancer
Registration Number
JPRN-UMIN000034782
Lead Sponsor
Japan Esophageal Society
Brief Summary

The median survival time after TEVAR was 135 days in the hemorrhage or impending hemorrhage group and 378 days in the preoperative prophylaxis group. Eighteen patients underwent esophagectomy after TEVAR. No hemorrhagic event was observed during the perioperative period. The median survival time of the patients who underwent esophagectomy was 373 days.

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
41
Inclusion Criteria

Not provided

Exclusion Criteria

nothing

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath